AffaMed Therapeutics announced this week that it has received a Clinical Trial Application (CTA) approval from Chinese regulators to conduct a phase 3 clinical trial of Samsung Bioepis’ biosimilar trastuzumab, SB3.
AffaMed Therapeutics announced this week that it has received a Clinical Trial Application (CTA) approval from Chinese regulators to conduct a phase 3 clinical trial of Samsung Bioepis’ biosimilar trastuzumab, SB3.
SB3, also referred to as AMT901, is approved in the United States and the European Union under the name Ontruzant. The newly announced phase 3 study is expected to begin in the first quarter of 2020.
Approval of the application was based on a review of a comprehensive data package that included results from a clinical comparative study that found no clinically meaningful differences, in terms of efficacy and safety, between the biosimilar and the reference product in patients who have HER2-positive breast cancer.
“This CTA approval is an important milestone for AffaMed as we transition to a clinical-stage biotechnological company,” said Nathan Pang, MBBS, EMBA, chief executive officer of AffaMed, in a statement. “We are fully geared up to initiate this clinical development program, with the goal of providing AMT901 to help more Chinese patients at an affordable price.”
This new development comes after Samsung Bioepis reached a February 2019 agreement with private equity firm C-Bridge Capital to allow the drug maker to expand its reach into mainland China. Under the terms of the agreement, C-Bridge established AffaMed as a new company designed to collaborate with Samsung Bioepis on clinical development, regulatory activities, and commercialization of biosimilar products in China. In return, Samsung Bioepis will receive an upfront payment and royalties on sales.
In February, the parties announced that the agreement would cover multiple biosimilar candidates in Samsung Bioepis’ pipeline, including a ranibizumab biosimilar referencing Lucentis. The companies are also developing an aflibercept biosimilar, referencing Eylea.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Phase 1 Study Finds Comparable PK, PD Parameters in Biosimilar GP40141 vs Reference Romiplostim
November 25th 2023A phase 1 analysis confirms that romiplostim biosimilar candidate GP40141 has comparable pharmacokinetic (PK) and pharmacodynamic (PD) parameters in healthy volunteers compared with the reference product.
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).